To quantify the effect of tumor-specific ABCG2 inhibition on topotecan accumulation, we developed a reverse phase high-performance liquid chromatography (RP-HPLC) assay to determine Ko143 concentrations in plasma and tumor matrix, using FTC as an internal standard (Zander et al., submitted for publication). The gene discussed is ABCG2; the disease is neoplasm.